Sarabjot Pabla: Understanding HLA Loss in Cancer is a Game Changer in Immune Evasion and Treatment
Sarabjot Pabla, Head of Clinical and Research Bioinformatics at OmniSeq, shared a post on LinkedIn
“Understanding HLA Loss in Cancer: A Game Changer in Immune Evasion and Treatment
The loss of Human Leukocyte Antigen (HLA) expression is a key mechanism by which tumors evade the immune system. This not only allows tumors to grow unchecked but also complicates the effectiveness of immunotherapies.
From genetic alterations and epigenetic modifications to transcriptional and post-translational changes, several mechanisms contribute to Human Leukocyte Antigen (HLA) loss. This impacts immune recognition, prognostic markers, and therapeutic strategies.
To delve deeper into how we can counteract this phenomenon and enhance cancer treatment outcomes, check out my latest short article!”
Further Reading.
Source: Sarabjot Pabla/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023